{
  "docId": "019de077-62f6-7619-b3d4-93c2a4cadb7d",
  "docSlug": "491e9b124c7ffd2bd1d8681cd2680c6c",
  "documentTitle": "OmniAb | Results Presentation Deck | 16 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 16,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "precedent_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 30,
  "notes": "The table uses a Gantt-style visualization to show the clinical phase of various drug programs. Notes at the bottom clarify specific program statuses and licensing terms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-62f6-7619-b3d4-93c2a4cadb7d/15",
  "deckHref": "/decks/019de077-62f6-7619-b3d4-93c2a4cadb7d",
  "deckJsonHref": "/decks/019de077-62f6-7619-b3d4-93c2a4cadb7d.json",
  "deckAnchorHref": "/decks/019de077-62f6-7619-b3d4-93c2a4cadb7d#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved and marketed in China. Teclistamab is approved and marketed in the US and EU with $35M launch milestones paid. JNJ-78306358 is a Johnson & Johnson investigational bispecific therapy with completed Phase 1 study. On October 31, 2023 Amgen announced plans to discontinue Phase 1 study of AMG 340 in mCRPC. On November 6, 2024 Genmab announced plans to terminate Phase 1/2 study of GEN1047 in malignant solid tumors. Indicates program with fully paid license from OMT, Inc. prior to acquisition. Programs discovered by Teneobio under a fully paid license. Future programs discovered under license agreement are subject to downstream economics.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0576f0b7-4c5d-4925-8877-30ff2e60f723",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.86,
        "x": 0.07,
        "y": 0.1
      },
      "kind": "table",
      "text": "PartnerM, Program, Source Animal, Therapy Area, Target, Phase 1, Phase 2, Phase 3, Registration, Approved",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c83ae9f-3534-4694-a4aa-0c2c8bc17cbf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.87,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline AS OF 9/30/2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf675823-349a-4658-ba6f-27774dd06205",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Valuation: Precedent transactions",
      "slug": "precedent-transactions",
      "agent": "architect",
      "layer": "slide",
      "matchId": "bc7f65c4-f377-484d-ae8f-76379db193bd",
      "evidence": "PartnerM, Program, Source Animal, Therapy Area, Target, Phase 1, Phase 2, Phase 3, Registration, Approved",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "c139da34-922c-4d46-8337-56a1a3002118",
      "evidence": "The table uses horizontal bars to represent the clinical phase progression of drug programs.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}